MedTrace Logo

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

NCT00902772 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-09-23

No results posted yet for this study

Summary

The purpose of this study is to examine the abuse potential of AZD7325.

Conditions

  • Recreational CNS Depressant Use

Interventions

DRUG

Lorazepam

mg, oral dose

DRUG

AZD7325

mg, oral dose

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Myroslava K Romach, MD · Kendle Early Stage - Toronto

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Months
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Completion
2009-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902772 on ClinicalTrials.gov